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Summary:Clinical features of asthmatics with a low %FVC «80%) were studied in
relation to airway inflammation and clinical asthma types. 1. Twenty four (75.0%) of the
32 sUbjects with a low %FVC had steroid-dependent intractable asthma. 2. A significant
association between %FVC value and clinical asthma type was found. The value of %FVC
was significantly lower in subjects with type II asthma (bronchiolar obstruction), in which
significantly decreased proportion of Iymphocytes,and significantly increased propor-
tion of neutrophils in bronchoalveolar lavage (BAL) fluid were observed, than in those
with type la-1 (simple bronchoconstriction) with (P<0.001) and without glucocorticoid
therapy (P<0.02). 3. The %FVC value was significantly improved after treatment in type Ib
(hypersecretion) with BAL eosinophilia, but not in those with type II with BAL
neutrophilia. These results demonstrate that marked decrease of %FVC in patients with
asthma correlated with airway inflammation, and that airway reversibility by medication
is very low in patients with type II asthma.
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Introduction
When a relevant allergen is inhaled by patients with
asthma, airway narrowing develops at two different
phases; within 30 min of the inhalation (immediate
asthmatic reaction, IAR), and within 6 to 8 hours (late
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asthmatic reaction, LAR)(1-3). The magnitude and
duration of hyperresponsiveness are speculated to be
related to the LAR (4, 5), which is associated with
migration of inflammatory cells, predominantly ac-
tivated T lymphocytes and eosinophils, into the air-
ways (6, 7). Thus, airway inflammation is a common
feature in asthma (8-11), leading to decrease in
bronchial reversibility by medications.
We previously reported (12-15) that asthma can be
classified by clinical symptoms into three clinical
types, which are closely related to airway inflam-
mation; type lb asthma is characterized by increased
proportion of eosinophils (16) in bronchoalveolar
lavage (BAL) fluid, and type 11 asthma by increased
proportion of BAL neutrophils. Our studies also
showed that ventilatory parameters such as FEV1.0
and V25 are affected by the proportion of in-
flammatory cells in the airways (12).
Airway narrowing caused by inhalation of allergen
and the other stimuli can be estimated by measuring
ventilatory function, routinely by a 20% fall in forced
expiratory volume in 1 second (FEV1.0), which is the
most common in clinical examination. The airway
narrowing is often improved immediately after inhala-
tion of bronchodilators. Many of patients with asthma
show a predominant decrease in FEV1.0%, however,
some of patients have a predominant decrease in
forced vital capacity (FVC). In this study, clinical
features of asthmatics with a low %FVC were ana-
lyzed in relation to clinical asthma type and airway
inflammation.
Subjects and Methods
The subjects of this study were 32 asthmatics (12
females and 20 males) with a low %FVC under 80%.
Their mean age was 61.0 years (range 23-77 years),
and the age at onset was 45.2 years (rang 3-73 years).
The subjects were divided into 4 groups according to
the value of %FVC; 75-79%, 70-74%, 60-69% and ~
59%, and 4 groups by age; 20-49, 50-59, 60-69, and
70+ years. All subjects were admitted at our hospital
and had drug medication and spa therapy (17, 18) for
1-3 months.
Asthma classification was performed by the method
previously described (12, 13); Ia. simple bronc-
hoconstriction type, lb. bronchoconstriction + hy-
persecretion type, and 11. bronchiolar obstruction type.
The criteria were as follows:
Type lao Simple bronchoconstriction type: Patients
with symptoms such as wheezing and dyspnea which
are mainly elicited by bronchoconstriction. In this
study, we divided this type into two subtypes accord-
ing to the amount of expectoration: 0-49 mIJday (Type
la-I) and 50-59 mIJday (Type la-2).
Type lb. Bronchoconstriction + hypersecretion type:
Patients with symptoms due to hypersecretion (more
than 100 mIJday of expectoration), in addition to
bronchoconstriction.
Type 11. Bronchiolar obstruction type: Patients with
symptoms mainly elicited by bronchiolar obstruction.
Furthermore, subjects with type la-l were divided
into two groups; with (S+) and without long-term
regimen of glucocorticoids (S-).
BAL was carried out according to a previously
reported method (19-21) when the subjects were
attack-free. Informed consent for this BAL procedure
was obtained from all study subjects. The aspirates
obtained by BAL were filtered through a sterile steel
mesh, and the filtrates were centrifuged at 300 g for 10
min at 4 "C , and the cell pellet was resuspended in
Tris ACM. Smear preparations were made using the
cell suspension. The slides were air dried and stained
with May-Gi~msa stain. A differential cell count was
performed on 500 cells excluding epithelial cells. In
this study, the mean recovery rate was 26.8 ± 9.5%
(mean ± SD). The total number of cells aspirated in
the BAL fluid was 9.53 ± 1O.2xI06• The results were
expressed as a percentage of the total cells.
Ventilatory function tests, using a Box Spiror 81S
(Chest Co) were carried out in all patients when they
were asymptomatic.
The level of serum cortisol was measured by
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Table 1. Characteristics of asthma patients with a low
%FVC studied
Figure 1. Correlation between %FVC value and age in
asthma patients with a low %FVC.
•
70-
"FVC
No of NJo Age at onset IgE S~Cortisolpatients (yelrs) (ye.rs) (IU/ml)
75·79 " II 60.5 41.1 460 6.8
(16-IOZO) (2.4-15.9)
70-74 " 10 61.3 46.Z ZI1 4.8
(Z7- 546) (1.6-12.1)
60·69" 4 55.0 35.0 759 6.Z
(Z37-1962) (1.0-I3.Z)
~59 " 64.7 56.1 873 8.1
(106-2798) (1.3-16.2)
la-l (5-) a 60.9 17.Zc 1.3 d Z.2 98 72.3 79.4
± 7.7 ± 6.6 ± 9.8 ± 6.7 ± 1.3 ±1.7
la-' (5+) 8 75.Z b 64.8 79.8 14.7 1.3" 4.Z h
± 4.0 ±13.0 ± 12.Z ± 11.8 ± 0.8 ± 4.5
10-2 67.8 62.4 74.3 1Z.8 5.7 7.0
± 6.3 ± 7.1 ± 8.6 ± 4.3 ± 6.2 ±6.1
Ib 70.0 60.8 66.7 1'1.7 1.41 15.Z9h
±10.1 ± 3.7 ±18.8 ± 5.5 ± 1.2 ±13.4
II ab 47.7 5.3c 39.4defl1.255.1 44.1
±14.7 ± 10.4 ±2Z.2 ± 8.6 ±33.6 ±16.2
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BALjbronchoalveolar lavage, Mac; macrophages, Lym;
lymphocytes, Neut; neutrophils. Eos; eosinophils. S+; patients
with glucocorticoid therapy, S·; patients without
glucocorticoid therapy. a and gjp<O.02. b. d, and e;p<O.OOl. c ,f
and h; p<0.05.
Table 2. Ventilatory function and cellular composition
of BAL fluid in patients with asthma classified
by clinical symptoms
Results
radioimmunoassay (RIA) at 7 to 8 o'clock in the
morning within a few days after their admission.
Statistically significant differences of the mean were
estimated using the unpaired and paired Student's t
test. A p value of <0.05 was regarded as significant.
Twenty four (75.0%) of the 32 subjects were
evaluated as having steroid-dependent intractable
asthma (SOIA), since they had been treated with oral
glucocorticoids (5-20 mg/day of prednisolone) and
inhaled glucocorticoids (200-600,ug/day of beclomet-
hasone) for more than 2 years. All of the 8 patients
without SDlA had type la-I asthma.
Table 1 shows characteristics of subjects classified
by the value of %FVC. The level of serum cortisol was
lowest in subjects with %FVC between 70 and 74%.
The difference in serum cortisol levels was not
significant among the four groups. Mean age and age
at onset were lowest in patients with %FVC between
60 and 69%, however, any correlation was not found
between age and %FVC value (Fig. 1).
Table 2 shows a correlation between ventilatory
function and the proportion of BAL cells in the four
clinical asthma types. The %FVC value was signifi-
cantly lower in patients with type II asthma than in
those with type la-I (S-; p<O.02, S+; p<O.OOl) (Fig.2).
The value of FEV 1.0% was not significantly different
among the four asthma types (Fig.3). Regarding the
proportion of BAL cells, the proportion of BAL
lymphocytes was significantly lower in patients with
type II asthma than in those with type la-I (S-)
(p<O.05). The proportion of BAL neutrophils was
significantly larger in patients with type II asthma than
in those with type la-I (S-; p<O.OOI, S+; p<O.OOI) and
type lb (p<0.05). In contrast, the proportion of BAL
eosinophils was significantly larger in patients with
type lb compared to that in those with type Ia-l (S-;
p<O.02, S+; p<O.OO5).
To assess whether a low FVC value in these patients
is reversible or not, the value was compared before
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Figure 4. FVC values before ( • ) and after
treatment ( 0 ) in patients with asthma
classified by clinical symptoms. S+; patients
with glucocorticoid therapy, S-; patients
without glucocorticoid therapy. a and d;
p<O.OOI, b and c; p<0.02.
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Figure 2. %FVC in patients with asthma classified by
clinical symptoms. a;p<0.02, b;p<O.Ol.
A significant increase in FEVl.O after the treatment
was observed in patients with type la-l (S-)(p<0.05)
and Ib (p<0.05). However, in the other asthma types, a
significant difference was not present between the
values in FEVl.O before and after the treatment
(Fig.5).
Figure 5. FEVl.O values before ( • ) and after
treatment ( 0 ) in patients with asthma
classified by clinical symptoms. S+; patients
with glucocorticoid therapy, S-; patients wit-
hout glucocorticoid therapy. a; p<0.05, b;
p<0.05.
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Figure 3. FEVl.O% in patients with asthma classified
by clinical symptoms.
and after the treatment (complex spa therapy (17, 18».
The FVC value tended to increase after the treatment
in all groups classified by clinical symptoms. A
significant increase in FVC after the treatment was
found in patients with type la-l (S-; p<O.OOI, S+;
p<0.02), la-2 (p<0.02). and Ib (p<O.OOl). However, the
increase in FVC after the treatment was not significant
1a-l
(5- )
la-l la-2 Ib
(5+)
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Discussion
Bronchial inhalation challenge with allergen causes
acute bronchoconstriction and late asthmatic reactions
(1-3). Allergen-induced airway narrowing is usually
evaluated by a 20% fall of FEVI.O. However, recent
studies by Gibbsons et al. demonstrate that measure of
a 20% fall in FEVI.O during allergen-induced asth-
matic reactions does not evaluate excessive bronc-
hoconstriction, which is the most important abnormali-
ty in asthma, since it puts patients at risk for serious
illness (22). They suggest that a fall in FVC refrects
excessive airway narrowing, which is an important
determinant of asthma severity. Thus, they recommend
that measuring %fall in FVC when FEVI.O falls by
20% is a safe mothod of detecting excessive bronc-
hoconstriction. Patients with greater fall in FVC
during bronchial challenge test are more likely to have
excerbations than those with relatively smaller falls in
FVC. Our results also show that patients with a greater
decrease in %FVC have more severe asthma, often
requiring systemic glucocorticoid therapy, than those
with smaller fall in %FVC. In fact, 24 (75.0%) of the
32 patients with a low %FVC had SOlA.
When airway smooth muscle contraction produces
unlimited bronchoconstriction to the extent that airway
closure occurs, this results in an increase in residual
volume (RV) with a corresponding decrease in vital
capacity (Ve). It has been shown that RV increases
(23, 24) and VC falls (25) significantly in asthma
patients during allergen-induced bronchoconstriction.
It has been clinically observed that many of patients
with asthma show a predominant fall in FEVI.OIFVC,
whereas some of them show a predominant fall in
FVC. In this study, association between dicrease in
%FVC and clinical asthma types related to airway
inflammation was examined in asthmatics whose
%FVC was under 80%. A decrease in %FVC was not
related to patient age, suggesting that decrease in
%FVC is not due to aging. In clinical types of asthma,
%FVC value was significantly lower in patients with
type II asthma, in which the proportion of BAL
neutrophils was markedly increased, than in those with
type la-l and type lb.
The decreased value of %FVC showed a tendency
to increase after the treatment including complex spa
therapy (17,18). A significant increase in FVC was
obserbed after the treatment in patients with type la-I,
la-2 and lb. However, the FVC value in patients with
type II did not increase significantly after the treatment
compared to the value before the treatment. In con-
trast, the value of FEVI.O was significantly improved
after the treatment only in patients with type la-l (S-).
These results demonstrate that a decrease in %FVC in
patients with asthma is related to disease severity. The
results also suggest that improvement of decreased
%FVC value after the treatment is associated with
airway inflammation; a significant inprovement of
FVC was found in type Ib asthma accompanied with
BAL eosinophilia, but not in type II asthma with BAL
neutrophilia.
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気管支職息患者における努力肺活量(%FVC)の
低下と気道炎症ならびに臨床病型との関連
光延文裕,御船尚志,保崎泰弘,芦田耕三,柘野
浩史,岡本 誠,原田誠之,湯本英一郎,高田真
吾,谷崎勝朗,越智浩二1),原田英雄1),長谷川
晴巳2),
岡山大学医学部三朝分院内科
臨床検査医学1)
鳥取市立病院内科2)
努力肺活量(%FVC)低値を示す気管支鴨息の臨床
病態を明らかにするために気道炎症ならびに臨床
病型との関連について検討を行った｡%FVCが
80%未満の気管支瑞息患者32名を対象として,
34
bronchialtreetodifferentstimuli.Bronches18:439,
1968.
スパイロメトリー,気管支肺胞洗浄(BAL)を施
行し,臨床病態を解析し,治療効果の評価を行なっ
た｡
1.対象中24名(75%)の患者がステロイド依存性
重症難治性鴨息であった｡2.細気管支閉塞型嘱
息患者において,%FVC値の有意の低下が認め
られ,BAL液中のリンパ球の減少と好中球の増
加が認められた｡3.FVC 値,FEV1.0億の治療に
よる改善は,BAL液中好酸球の増加を示す過分
泌型嘱息においては認められたが,BAL液中好
中球の増加を示す細気管支閉塞型嶋息においては
認められなかった｡
以上より鴨息患者における%FVC値の低下は気
道炎症と関連しており,細気管支閉塞型瑞息にお
ける治療による可逆性は著しく低下していること
が示唆された｡
